Twist Bioscience Corp (NASDAQ: TWST) shares plummeted 19.53% in pre-market trading on Friday, following the release of its fiscal 2025 fourth quarter results and 2026 guidance. The synthetic DNA technology company reported mixed results, with revenue beating expectations but earnings falling short of analyst estimates.
For the fourth quarter ended September 30, 2025, Twist Bioscience reported a net loss of $0.45 per share, missing the analyst consensus estimate of $0.43 loss per share. This represents a 4.65% larger loss than expected, despite showing a 23.73% improvement from the $0.59 loss per share in the same quarter last year. On a positive note, the company's quarterly sales reached $99.009 million, surpassing the analyst consensus estimate of $97.317 million by 1.74% and marking a 16.88% increase from $84.710 million in the year-ago period.
Adding to investor concerns, Twist Bioscience's fiscal 2026 guidance came in slightly below market expectations. The company forecasts total revenue for fiscal 2026 to be in the range of $425 million to $435 million, compared to the FactSet consensus estimate of $431.9 million. For the upcoming first quarter of fiscal 2026, Twist expects revenue between $100 million and $101 million, which is in line with the current FactSet estimate of $100.1 million. The cautious outlook, combined with the earnings miss, appears to have triggered the significant pre-market sell-off as investors reassess the company's growth trajectory and profitability prospects.
Comments